Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors, has announced its participation in an upcoming panel discussion following the United European Gastroenterology Week (UEGW) Conference 2025.
The panel will be moderated by Wedbush Securities analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Dr. Marla Dubinsky from Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., Shattuck's CEO, will represent the company at the event scheduled for October 8, 2025, from 10:00 AM to 12:00 PM EST.
Shattuck Labs (NASDAQ: STTK), un’azienda biotecnologica focalizzata sullo sviluppo di terapie innovative mirate ai recettori della TNF superfamiglia, ha annunciato la propria partecipazione a una prossima tavola rotonda dopo la conferenza UE Week 2025.
La tavola verrà moderata dagli analisti di Wedbush Securities Martin Fan, Ph.D. e David Nierengarten, Ph.D., e vedrà la partecipazione dell’opinione leader Dr. Marla Dubinsky del Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., CEO di Shattuck, rappresenterà l’azienda all’evento previsto per 8 ottobre 2025, dalle 10:00 alle 12:00 EST.
Shattuck Labs (NASDAQ: STTK), una empresa biotecnológica centrada en desarrollar terapias novedosas que apunten a receptores de la superfamilia TNF, ha anunciado su participación en una próxima mesa redonda tras la conferencia UE Week 2025 de United European Gastroenterology Week (UEGW).
La mesa será moderada por los analistas de Wedbush Securities Martin Fan, Ph.D. y David Nierengarten, Ph.D., con la figura clave Dr. Marla Dubinsky del Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., CEO de Shattuck, representará a la empresa en el evento programado para el 8 de octubre de 2025, de 10:00 a 12:00 p.m. EST.
Shattuck Labs (NASDAQ: STTK), TNF 슈퍼패밀리 수용체를 표적으로 하는 새로운 치료제를 개발하는 바이오기술 기업은 다가오는 UE Week 2025 컨퍼런스 이후 열리는 패널 토론에 참여한다는 소식을 밝혔다.
패널은 Wedbush Securities 분석가 Martin Fan 박사와 David Nierengarten 박사가 진행하며 Mount Sinai Health System의 핵심 의학자 Dr. Marla Dubinsky가 함께한다. Taylor Schreiber, M.D., Ph.D., Shattuck의 CEO가 2025년 10월 8일 동부표준시 기준 오전 10시부터 12시까지 예정된 행사에서 회사를 대표할 예정이다.
Shattuck Labs (NASDAQ : STTK), entreprise biotechnologique axée sur le développement de thérapies novatrices ciblant les récepteurs de la superfamille TNF, a annoncé sa participation à une prochaine discussion en panel après la conférence UE Week 2025 de United European Gastroenterology Week (UEGW).
Le panel sera modéré par les analystes de Wedbush Securities Martin Fan, Ph.D. et David Nierengarten, Ph.D., et présentera la figure clé Dr. Marla Dubinsky du Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., PDG de Shattuck, représentera l’entreprise lors de l’événement prévu le 8 octobre 2025, de 10h00 à 12h00 EST.
Shattuck Labs (NASDAQ: STTK), ein Biotechnologieunternehmen, das neue Therapeutika entwickelt, die auf Receptoren der TNF-Superfamilie abzielen, hat seine Teilnahme an einer kommenden Podiumsdiskussion nach der United European Gastroenterology Week (UEGW) Conference 2025 bekannt gegeben.
Die Debatte wird von Wedbush Securities-Analysten Martin Fan, Ph.D. und David Nierengarten, Ph.D. moderiert, mit Dr. Marla Dubinsky vom Mount Sinai Health System als KOL. Taylor Schreiber, M.D., Ph.D., CEO von Shattuck, wird das Unternehmen bei der am 8. Oktober 2025 von 10:00 bis 12:00 Uhr EST geplanten Veranstaltung vertreten.
Shattuck Labs (NASDAQ: STTK)، شركة تكنولوجيا حيوية تركز على تطوير علاجات جديدة تستهدف مستقبل TNF من عائلة TNF، أعلنت عن مشاركتها في جلسة نقاشية قادمة تلي مؤتمر UE Week 2025.
سيُدار الجلسة من قبل محللي Wedbush Securities مارتن فان، دكتوراه، وديفيد نييرينغارتن، دكتوراه، وسيشارك الدكتور مارلا دوبينسكي من Mount Sinai Health System. سيمثل Taylor Schreiber، دكتور في الطب، ودكتور في الطب، الرئيس التنفيذي لشركة Shattuck، الشركة في الحدث المقرر 8 أكتوبر 2025، من 10:00 صباحاً إلى 12:00 مساءً بتوقيت شرق الولايات المتحدة.
Shattuck Labs（纳斯达克：STTK），一家专注于开发针对 TNF 超家族受体的新型治疗药物的生物技术公司，宣布将参与在2025年欧洲胃肠周（UEGW）会议之后举行的圆桌讨论。
圆桌将由 Wedbush Securities 的分析师 Martin Fan 博士和 David Nierengarten 博士主持，Mount Sinai Health System 的关键意见领袖 Marla Dubinsky 博士 将出席。Shattuck 的首席执行官 Taylor Schreiber 博士将代表公司出席定于 2025年10月8日，美国东部时间上午10点至12点举行的活动。
- None.
- None.
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be moderated by covering analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., and will feature KOL Marla Dubinsky, M.D., Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai Health System.
Conference Details
Format: Panel Discussion
Session Title: Wedbush UEGW Conference 2025 Rewind
Moderators: Martin Fan, Ph.D. and David Nierengarten, Ph.D.
Shattuck Participant: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: October 8, 2025
Time: 10:00am - 12:00pm EST
Website Link: Here
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer the potential for higher efficacy and lower immunogenicity in comparison to TL1A blocking antibodies. SL-325 is currently being studied in a Phase 1 clinical trial.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. Shattuck is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) participating in the Wedbush Securities panel discussion?
Who are the moderators for the Shattuck Labs UEGW Conference panel?
Who is representing Shattuck Labs at the Wedbush UEGW Conference panel?
What is the focus of Shattuck Labs' therapeutic development?
